{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T14:28:13Z","timestamp":1794320893539,"version":"4.9.0"},"reference-count":125,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,13]],"date-time":"2021-01-13T00:00:00Z","timestamp":1610496000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,1,13]],"date-time":"2021-01-13T00:00:00Z","timestamp":1610496000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["P20GM109025"],"award-info":[{"award-number":["P20GM109025"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["U01NS093334"],"award-info":[{"award-number":["U01NS093334"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["R01AG053798"],"award-info":[{"award-number":["R01AG053798"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurodegeneration"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Successful development of agents that improve cognition and behavior in Alzheimer\u2019s disease (AD) is critical to improving the lives of patients manifesting the symptoms of this progressive disorder.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>There have been no recent approvals of cognitive enhancing agents for AD. There are currently 6 cognitive enhancers in Phase 2 trials and 4 in phase 3. They represent a variety of novel mechanisms. There has been progress in developing new treatments for neuropsychiatric symptoms in AD with advances in treatment of insomnia, psychosis, apathy, and agitation in AD. There are currently 4\u2009AD-related psychotropic agents in Phase 2 trials and 7 in Phase 3 trials. Many novel mechanisms are being explored for the treatment of cognitive and behavioral targets. Progress in trial designs, outcomes measures, and population definitions are improving trial conduct for symptomatic treatment of AD.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Advances in developing new agents for cognitive and behavioral symptoms of AD combined with enhanced trial methods promise to address the unmet needs of patients with AD for improved cognition and amelioration of neuropsychiatric symptoms.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13024-021-00424-9","type":"journal-article","created":{"date-parts":[[2021,1,13]],"date-time":"2021-01-13T11:05:42Z","timestamp":1610535942000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":184,"title":["New approaches to symptomatic treatments for Alzheimer\u2019s disease"],"prefix":"10.1186","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8944-4158","authenticated-orcid":false,"given":"Jeffrey","family":"Cummings","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,13]]},"reference":[{"key":"424_CR1","doi-asserted-by":"crossref","unstructured":"Masters CL, Bateman R, Blennow K, Rowe CC, Sperling RA, Cummings JL. Alzheimer's disease. Nat Rev Dis Primers. 2015;1:150.","DOI":"10.1038\/nrdp.2015.56"},{"issue":"10043","key":"424_CR2","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/S0140-6736(15)01124-1","volume":"388","author":"P Scheltens","year":"2016","unstructured":"Scheltens P, Blennow K, Breteler MM, de Strooper B, Frisoni GB, Salloway S, et al. Alzheimer's disease. Lancet. 2016;388(10043):505\u201317.","journal-title":"Lancet."},{"issue":"4\u20135","key":"424_CR3","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.neuropharm.2010.02.010","volume":"59","author":"PT Francis","year":"2010","unstructured":"Francis PT, Ramirez MJ, Lai MK. Neurochemical basis for symptomatic treatment of Alzheimer's disease. Neuropharmacology. 2010;59(4\u20135):221\u20139.","journal-title":"Neuropharmacology."},{"issue":"2","key":"424_CR4","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.mcna.2018.10.009","volume":"103","author":"A Atri","year":"2019","unstructured":"Atri A. The Alzheimer's disease clinical spectrum: diagnosis and management. Med Clin North Am. 2019;103(2):263\u201393.","journal-title":"Med Clin North Am"},{"issue":"6","key":"424_CR5","volume":"20","author":"J Cummings","year":"2020","unstructured":"Cummings J, Lee G, Ritter A, Sabbagh M, Zhong K. Alzheimer's disease drug development pipeline: 2020. Alzheimer Dement TRCI. 2020;20(6):e12050.","journal-title":"Alzheimer Dement TRCI"},{"issue":"4","key":"424_CR6","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/alzrt269","volume":"6","author":"JL Cummings","year":"2014","unstructured":"Cummings JL, Morstorf T, Zhong K. Alzheimer's disease drug-development pipeline: few candidates, frequent failures. Alzheimers Res Ther. 2014;6(4):37.","journal-title":"Alzheimers Res Ther"},{"issue":"9","key":"424_CR7","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1001\/archinte.158.9.1021","volume":"158","author":"SL Rogers","year":"1998","unstructured":"Rogers SL, Doody RS, Mohs RC, Friedhoff LT. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group. Arch Intern Med. 1998;158(9):1021\u201331.","journal-title":"Arch Intern Med"},{"issue":"2","key":"424_CR8","doi-asserted-by":"publisher","first-page":"615","DOI":"10.3233\/JAD-132690","volume":"41","author":"CC Tan","year":"2014","unstructured":"Tan CC, Yu JT, Wang HF, Tan MS, Meng XF, Wang C, et al. Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer's disease: a systematic review and meta-analysis. J Alzheimers Dis. 2014;41(2):615\u201331.","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"424_CR9","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s13195-018-0457-9","volume":"10","author":"KX Dou","year":"2018","unstructured":"Dou KX, Tan MS, Tan CC, Cao XP, Hou XH, Guo QH, et al. Comparative safety and effectiveness of cholinesterase inhibitors and memantine for Alzheimer's disease: a network meta-analysis of 41 randomized controlled trials. Alzheimers Res Ther. 2018;10(1):126.","journal-title":"Alzheimers Res Ther"},{"issue":"3","key":"424_CR10","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1212\/WNL.57.3.489","volume":"57","author":"B Winblad","year":"2001","unstructured":"Winblad B, Engedal K, Soininen H, Verhey F, Waldemar G, Wimo A, et al. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology. 2001;57(3):489\u201395.","journal-title":"Neurology."},{"issue":"5","key":"424_CR11","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1017\/S1041610209990354","volume":"21","author":"J Rodda","year":"2009","unstructured":"Rodda J, Morgan S, Walker Z. Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine. Int Psychogeriatr. 2009;21(5):813\u201324.","journal-title":"Int Psychogeriatr"},{"issue":"3","key":"424_CR12","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1176\/appi.ajp.161.3.532","volume":"161","author":"JL Cummings","year":"2004","unstructured":"Cummings JL, Schneider L, Tariot PN, Kershaw PR, Yuan W. Reduction of behavioral disturbances and caregiver distress by galantamine in patients with Alzheimer's disease. Am J Psychiatry. 2004;161(3):532\u20138.","journal-title":"Am J Psychiatry"},{"issue":"4537","key":"424_CR13","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1126\/science.7058341","volume":"215","author":"PJ Whitehouse","year":"1982","unstructured":"Whitehouse PJ, Price DL, Struble RG, Clark AW, Coyle JT, Delon MR. Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. Science. 1982;215(4537):1237\u20139.","journal-title":"Science."},{"issue":"7","key":"424_CR14","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1093\/brain\/awy132","volume":"141","author":"H Hampel","year":"2018","unstructured":"Hampel H, Mesulam MM, Cuello AC, Farlow MR, Giacobini E, Grossberg GT, et al. The cholinergic system in the pathophysiology and treatment of Alzheimer's disease. Brain. 2018;141(7):1917\u201333.","journal-title":"Brain."},{"issue":"18","key":"424_CR15","doi-asserted-by":"publisher","first-page":"4124","DOI":"10.1002\/cne.23415","volume":"521","author":"MM Mesulam","year":"2013","unstructured":"Mesulam MM. Cholinergic circuitry of the human nucleus basalis and its fate in Alzheimer's disease. J Comp Neurol. 2013;521(18):4124\u201344.","journal-title":"J Comp Neurol"},{"issue":"1","key":"424_CR16","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1002\/agm2.12017","volume":"1","author":"H Guo","year":"2018","unstructured":"Guo H, Grajauskas L, Habash B, D'Arcy RC, Song X. Functional MRI technologies in the study of medication treatment effect on Alzheimer's disease. Aging Med (Milton). 2018;1(1):75\u201395.","journal-title":"Aging Med (Milton)"},{"issue":"5","key":"424_CR17","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1001\/archneur.62.5.721","volume":"62","author":"MS Mega","year":"2005","unstructured":"Mega MS, Dinov ID, Porter V, Chow G, Reback E, Davoodi P, et al. Metabolic patterns associated with the clinical response to galantamine therapy: a fludeoxyglucose f 18 positron emission tomographic study. Arch Neurol. 2005;62(5):721\u20138.","journal-title":"Arch Neurol"},{"key":"424_CR18","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/978-1-4939-7704-8_10","volume":"1750","author":"S Holiga","year":"2018","unstructured":"Holiga S, Abdulkadir A, Kloppel S, Dukart J. Functional magnetic resonance imaging in Alzheimer' disease drug development. Methods Mol Biol. 2018;1750:159\u201363.","journal-title":"Methods Mol Biol"},{"issue":"18","key":"424_CR19","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1056\/NEJM199210293271801","volume":"327","author":"KL Davis","year":"1992","unstructured":"Davis KL, Thal LJ, Gamzu ER, Davis CS, Woolson RF, Gracon SI, et al. A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. The Tacrine collaborative study group. N Engl J Med. 1992;327(18):1253\u20139.","journal-title":"N Engl J Med"},{"issue":"18","key":"424_CR20","doi-asserted-by":"publisher","first-page":"2523","DOI":"10.1001\/jama.1992.03490180055026","volume":"268","author":"M Farlow","year":"1992","unstructured":"Farlow M, Gracon SI, Hershey LA, Lewis KW, Sadowsky CH, Dolan-Ureno J. A controlled trial of tacrine in Alzheimer's disease. The Tacrine Study Group. JAMA. 1992;268(18):2523\u20139.","journal-title":"JAMA"},{"issue":"3","key":"424_CR21","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","volume":"12","author":"MF Folstein","year":"1975","unstructured":"Folstein MF, Folstein SE, McHugh PR. \"mini-mental state\". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189\u201398.","journal-title":"J Psychiatr Res"},{"key":"424_CR22","unstructured":"Guy W. Clinical Global Impressions. ECDEU Assessment Manual for Psychopharmacology\u2014Revised. . Rockville, MD: U.S. Department of Health, Education, and Welfare; Public Health Service, Alcohol; Drug Abuse, and Mental Health Administration; National Institute of Mental Health; Psychopharmacology Research Branch; Division of Extramural Research Programs; 1976."},{"issue":"11","key":"424_CR23","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1176\/ajp.141.11.1356","volume":"141","author":"WG Rosen","year":"1984","unstructured":"Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry. 1984;141(11):1356\u201364.","journal-title":"Am J Psychiatry"},{"key":"424_CR24","unstructured":"Leber P. Guidelines for the clinical evaluation of antidementia drugs. First draft. Technical Report. FDA Neuro-Pharm Group. 1990."},{"issue":"4","key":"424_CR25","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.trci.2016.07.001","volume":"2","author":"J Cummings","year":"2016","unstructured":"Cummings J, Morstorf T, Lee G. Alzheimer's drug-development pipeline: 2016. Alzheimers Dement (N Y). 2016;2(4):222\u201332.","journal-title":"Alzheimers Dement (N Y)"},{"issue":"3","key":"424_CR26","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.trci.2017.05.002","volume":"3","author":"J Cummings","year":"2017","unstructured":"Cummings J, Lee G, Mortsdorf T, Ritter A, Zhong K. Alzheimer's disease drug development pipeline: 2017. Alzheimers Dement (N Y). 2017;3(3):367\u201384.","journal-title":"Alzheimers Dement (N Y)."},{"key":"424_CR27","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.trci.2018.03.009","volume":"4","author":"J Cummings","year":"2018","unstructured":"Cummings J, Lee G, Ritter A, Zhong K. Alzheimer's disease drug development pipeline: 2018. Alzheimers Dement (N Y). 2018;4:195\u2013214.","journal-title":"Alzheimers Dement (N Y)."},{"key":"424_CR28","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.trci.2019.05.008","volume":"5","author":"J Cummings","year":"2019","unstructured":"Cummings J, Lee G, Ritter A, Sabbagh M, Zhong K. Alzheimer's disease drug development pipeline: 2019. Alzheimers Dement (N Y). 2019;5:272\u201393.","journal-title":"Alzheimers Dement (N Y)."},{"issue":"10","key":"424_CR29","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/s41422-019-0216-x","volume":"29","author":"X Wang","year":"2019","unstructured":"Wang X, Sun G, Feng T, Zhang J, Huang X, Wang T, et al. Sodium oligomannate therapeutically remodels gut microbiota and suppresses gut bacterial amino acids-shaped neuroinflammation to inhibit Alzheimer's disease progression. Cell Res. 2019;29(10):787\u2013803.","journal-title":"Cell Res"},{"issue":"4","key":"424_CR30","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/S1474-4422(15)70016-5","volume":"14","author":"MT Heneka","year":"2015","unstructured":"Heneka MT, Carson MJ, El Khoury J, Landreth GE, Brosseron F, Feinstein DL, et al. Neuroinflammation in Alzheimer's disease. Lancet Neurol. 2015;14(4):388\u2013405.","journal-title":"Lancet Neurol"},{"issue":"3","key":"424_CR31","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1007\/s12035-018-1188-4","volume":"56","author":"M Sochocka","year":"2019","unstructured":"Sochocka M, Donskow-Lysoniewska K, Diniz BS, Kurpas D, Brzozowska E, Leszek J. The gut microbiome alterations and inflammation-driven pathogenesis of Alzheimer's disease-a critical review. Mol Neurobiol. 2019;56(3):1841\u201351.","journal-title":"Mol Neurobiol"},{"issue":"2","key":"424_CR32","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1001\/jama.2017.20373","volume":"319","author":"A Atri","year":"2018","unstructured":"Atri A, Frolich L, Ballard C, Tariot PN, Molinuevo JL, Boneva N, et al. Effect of idalopirdine as adjunct to cholinesterase inhibitors on change in cognition in patients with Alzheimer disease: three randomized clinical trials. JAMA. 2018;319(2):130\u201342.","journal-title":"JAMA."},{"issue":"6","key":"424_CR33","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1080\/13543784.2018.1483334","volume":"27","author":"R Khoury","year":"2018","unstructured":"Khoury R, Grysman N, Gold J, Patel K, Grossberg GT. The role of 5 HT6-receptor antagonists in Alzheimer's disease: an update. Expert Opin Investig Drugs. 2018;27(6):523\u201333.","journal-title":"Expert Opin Investig Drugs"},{"issue":"8","key":"424_CR34","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1111\/jphp.12919","volume":"70","author":"S Verma","year":"2018","unstructured":"Verma S, Kumar A, Tripathi T, AK. Muscarinic and nicotinic acetylcholine receptor agonists: current scenario in Alzheimer's disease therapy. J Pharm Pharmacol. 2018;70(8):985\u201393.","journal-title":"J Pharm Pharmacol"},{"issue":"6","key":"424_CR35","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1093\/brain\/awy099","volume":"141","author":"O Sabri","year":"2018","unstructured":"Sabri O, Meyer PM, Graf S, Hesse S, Wilke S, Becker GA, et al. Cognitive correlates of alpha4beta2 nicotinic acetylcholine receptors in mild Alzheimer's dementia. Brain. 2018;141(6):1840\u201354.","journal-title":"Brain."},{"issue":"2","key":"424_CR36","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s13311-016-0511-x","volume":"14","author":"TN Chase","year":"2017","unstructured":"Chase TN, Farlow MR, Clarence-Smith K. Donepezil plus solifenacin (CPC-201) treatment for Alzheimer's disease. Neurotherapeutics. 2017;14(2):405\u201316.","journal-title":"Neurotherapeutics."},{"key":"424_CR37","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.trci.2018.03.004","volume":"4","author":"T Voss","year":"2018","unstructured":"Voss T, Li J, Cummings J, Farlow M, Assaid C, Froman S, et al. Randomized, controlled, proof-of-concept trial of MK-7622 in Alzheimer's disease. Alzheimers Dement (N Y). 2018;4:173\u201381.","journal-title":"Alzheimers Dement (N Y)"},{"issue":"6","key":"424_CR38","doi-asserted-by":"publisher","first-page":"450","DOI":"10.2165\/00002512-199711060-00004","volume":"11","author":"EE Avery","year":"1997","unstructured":"Avery EE, Baker LD, Asthana S. Potential role of muscarinic agonists in Alzheimer's disease. Drugs Aging. 1997;11(6):450\u20139.","journal-title":"Drugs Aging"},{"issue":"4","key":"424_CR39","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1001\/archneur.1997.00550160091022","volume":"54","author":"NC Bodick","year":"1997","unstructured":"Bodick NC, Offen WW, Levey AI, Cutler NR, Gauthier SG, Satlin A, et al. Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease. Arch Neurol. 1997;54(4):465\u201373.","journal-title":"Arch Neurol"},{"issue":"1","key":"424_CR40","doi-asserted-by":"publisher","first-page":"68","DOI":"10.2174\/1567205012666150921095924","volume":"13","author":"C Phillips","year":"2016","unstructured":"Phillips C, Fahimi A, Das D, Mojabi FS, Ponnusamy R, Salehi A. Noradrenergic system in Down syndrome and Alzheimer's disease a target for therapy. Curr Alzheimer Res. 2016;13(1):68\u201383.","journal-title":"Curr Alzheimer Res"},{"key":"424_CR41","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.phrs.2018.01.016","volume":"130","author":"M D'Amelio","year":"2018","unstructured":"D'Amelio M, Puglisi-Allegra S, Mercuri N. The role of dopaminergic midbrain in Alzheimer's disease: translating basic science into clinical practice. Pharmacol Res. 2018;130:414\u20139.","journal-title":"Pharmacol Res"},{"issue":"7","key":"424_CR42","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.10372","volume":"3","author":"G Koch","year":"2020","unstructured":"Koch G, Motta C, Bonni S, Pellicciari MC, Picazio S, Casula EP, et al. Effect of rotigotine vs placebo on cognitive functions among patients with mild to moderate Alzheimer disease: a randomized clinical trial. JAMA Netw Open. 2020;3(7):e2010372.","journal-title":"JAMA Netw Open"},{"key":"424_CR43","unstructured":"Ritter DMA, Thomas R, Andrews R, Lukic A, Revta C, et al., editors. The effects of rasagiline upon cerebral glucose metabolism, cognition, and tau in patients with mild to moderate Alzheimer\u2019s disease. San Diego: 12th Clinical Trials on Alzheimer\u2019s Disease Congress; 2019."},{"issue":"15","key":"424_CR44","doi-asserted-by":"publisher","first-page":"e1474","DOI":"10.1212\/WNL.0000000000008239","volume":"93","author":"LS Schneider","year":"2019","unstructured":"Schneider LS, Geffen Y, Rabinowitz J, Thomas RG, Schmidt R, Ropele S, et al. Low-dose ladostigil for mild cognitive impairment: a phase 2 placebo-controlled clinical trial. Neurology. 2019;93(15):e1474\u2013e84.","journal-title":"Neurology."},{"issue":"4","key":"424_CR45","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.3233\/JAD-161309","volume":"58","author":"S Nave","year":"2017","unstructured":"Nave S, Doody RS, Boada M, Grimmer T, Savola JM, Delmar P, et al. Sembragiline in moderate Alzheimer's disease: results of a randomized, double-blind, placebo-controlled phase II trial (MAyflOwer RoAD). J Alzheimers Dis. 2017;58(4):1217\u201328.","journal-title":"J Alzheimers Dis"},{"issue":"3","key":"424_CR46","doi-asserted-by":"publisher","first-page":"317","DOI":"10.2174\/1381612820666140826114601","volume":"21","author":"PR Heckman","year":"2015","unstructured":"Heckman PR, Wouters C, Prickaerts J. Phosphodiesterase inhibitors as a target for cognition enhancement in aging and Alzheimer's disease: a translational overview. Curr Pharm Des. 2015;21(3):317\u201331.","journal-title":"Curr Pharm Des"},{"key":"424_CR47","doi-asserted-by":"publisher","unstructured":"Boland K, Moschetti V, Dansirikul C, Pichereau S, Gheyle L, Runge F, Zimdahl-Gelling H, Sand M. A phase I, randomized, proof-of-clinical-mechanism study assessing the pharmacokinetics and pharmacodynamics of the oral PDE9A inhibitor BI 409306 in healthy male volunteers. Hum Psychopharmacol. 2017;32(1). https:\/\/doi.org\/10.1002\/hup.2569. PMID: 28120486.","DOI":"10.1002\/hup.2569"},{"issue":"1","key":"424_CR48","first-page":"1","volume":"38","author":"R Libro","year":"2017","unstructured":"Libro R, Bramanti P, Mazzon E. Endogenous glucocorticoids: role in the etiopathogenesis of Alzheimer's disease. Neuro Endocrinol Lett. 2017;38(1):1\u201312.","journal-title":"Neuro Endocrinol Lett"},{"issue":"5 Suppl","key":"424_CR49","first-page":"S364","volume":"10","author":"GJ Marek","year":"2014","unstructured":"Marek GJ, Katz DA, Meier A, Greco N, Zhang W, Liu W, et al. Efficacy and safety evaluation of HSD-1 inhibitor ABT-384 in Alzheimer's disease. Alzheimers Dement. 2014;10(5 Suppl):S364\u201373.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"424_CR50","doi-asserted-by":"publisher","first-page":"115","DOI":"10.3233\/JAD-160281","volume":"55","author":"A Dal-Pan","year":"2017","unstructured":"Dal-Pan A, Dudonne S, Bourassa P, Bourdoulous M, Tremblay C, Desjardins Y, et al. Cognitive-enhancing effects of a polyphenols-rich extract from fruits without changes in neuropathology in an animal model of Alzheimer's disease. J Alzheimers Dis. 2017;55(1):115\u201335.","journal-title":"J Alzheimers Dis"},{"key":"424_CR51","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.bbr.2016.05.052","volume":"311","author":"XH Gu","year":"2016","unstructured":"Gu XH, Xu LJ, Liu ZQ, Wei B, Yang YJ, Xu GG, et al. The flavonoid baicalein rescues synaptic plasticity and memory deficits in a mouse model of Alzheimer's disease. Behav Brain Res. 2016;311:309\u201321.","journal-title":"Behav Brain Res"},{"key":"424_CR52","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.neuroscience.2018.02.031","volume":"377","author":"H Izumi","year":"2018","unstructured":"Izumi H, Shinoda Y, Saito T, Saido TC, Sato K, Yabuki Y, et al. The disease-modifying drug candidate, SAK3 improves cognitive impairment and inhibits amyloid beta deposition in app knock-in mice. Neuroscience. 2018;377:87\u201397.","journal-title":"Neuroscience."},{"issue":"5","key":"424_CR53","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1002\/hipo.22837","volume":"28","author":"T Li","year":"2018","unstructured":"Li T, Jiao JJ, Holscher C, Wu MN, Zhang J, Tong JQ, et al. A novel GLP-1\/GIP\/Gcg triagonist reduces cognitive deficits and pathology in the 3xTg mouse model of Alzheimer's disease. Hippocampus. 2018;28(5):358\u201372.","journal-title":"Hippocampus."},{"issue":"5","key":"424_CR54","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/alzrt209","volume":"5","author":"DW Shineman","year":"2013","unstructured":"Shineman DW, Carman AJ, Dacks PA, Lane RF, Fillit HM. Progress in novel cognitive enhancers for cognitive aging and Alzheimer's disease. Alzheimers Res Ther. 2013;5(5):45.","journal-title":"Alzheimers Res Ther"},{"key":"424_CR55","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/bs.apha.2019.06.001","volume":"86","author":"KA Svensson","year":"2019","unstructured":"Svensson KA, Hao J, Bruns RF. Positive allosteric modulators of the dopamine D1 receptor: a new mechanism for the treatment of neuropsychiatric disorders. Adv Pharmacol. 2019;86:273\u2013305.","journal-title":"Adv Pharmacol"},{"issue":"1","key":"424_CR56","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s13195-015-0109-2","volume":"7","author":"A Atri","year":"2015","unstructured":"Atri A, Hendrix SB, Pejovic V, Hofbauer RK, Edwards J, Molinuevo JL, et al. Cumulative, additive benefits of memantine-donepezil combination over component monotherapies in moderate to severe Alzheimer's dementia: a pooled area under the curve analysis. Alzheimers Res Ther. 2015;7(1):28.","journal-title":"Alzheimers Res Ther"},{"issue":"3\u20134","key":"424_CR57","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1159\/000113712","volume":"5","author":"A Fisher","year":"2008","unstructured":"Fisher A. M1 muscarinic agonists target major hallmarks of Alzheimer's disease--the pivotal role of brain M1 receptors. Neurodegener Dis. 2008;5(3\u20134):237\u201340.","journal-title":"Neurodegener Dis"},{"key":"424_CR58","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1111\/j.1749-6632.1997.tb48495.x","volume":"826","author":"DK Lahiri","year":"1997","unstructured":"Lahiri DK, Farlow MR, Nurnberger JI Jr, Greig NH. Effects of cholinesterase inhibitors on the secretion of beta-amyloid precursor protein in cell cultures. Ann N Y Acad Sci. 1997;826:416\u201321.","journal-title":"Ann N Y Acad Sci"},{"issue":"5","key":"424_CR59","doi-asserted-by":"publisher","first-page":"703","DOI":"10.15252\/emmm.201606666","volume":"9","author":"YS Cheng","year":"2017","unstructured":"Cheng YS, Chen ZT, Liao TY, Lin C, Shen HC, Wang YH, et al. An intranasally delivered peptide drug ameliorates cognitive decline in Alzheimer transgenic mice. EMBO Mol Med. 2017;9(5):703\u201315.","journal-title":"EMBO Mol Med"},{"key":"424_CR60","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/bs.vh.2016.02.004","volume":"101","author":"CR Abraham","year":"2016","unstructured":"Abraham CR, Mullen PC, Tucker-Zhou T, Chen CD, Zeldich E. Klotho is a neuroprotective and cognition-enhancing protein. Vitam Horm. 2016;101:215\u201338.","journal-title":"Vitam Horm"},{"key":"424_CR61","doi-asserted-by":"publisher","unstructured":"Cummings J. Drug Development for Psychotropic, Cognitive-Enhancing, and Disease-ModifyingTreatments for Alzheimer's Disease. J Neuropsychiatry Clin Neurosci. 2020;appineuropsych20060152. https:\/\/doi.org\/10.1176\/appi.neuropsych.20060152. Online ahead of print. PMID: 33108950.","DOI":"10.1176\/appi.neuropsych.20060152"},{"issue":"1","key":"424_CR62","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1017\/S1041610214001963","volume":"27","author":"J Cummings","year":"2015","unstructured":"Cummings J, Mintzer J, Brodaty H, Sano M, Banerjee S, Devanand DP, et al. Agitation in cognitive disorders: international psychogeriatric association provisional consensus clinical and research definition. Int Psychogeriatr. 2015;27(1):7\u201317.","journal-title":"Int Psychogeriatr"},{"issue":"3","key":"424_CR63","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.3233\/JAD-190828","volume":"73","author":"CE Fischer","year":"2020","unstructured":"Fischer CE, Ismail Z, Youakim JM, Creese B, Kumar S, Nunez N, et al. Revisiting criteria for psychosis in Alzheimer's disease and related dementias: toward better phenotypic classification and biomarker research. J Alzheimers Dis. 2020;73(3):1143\u201356.","journal-title":"J Alzheimers Dis"},{"key":"424_CR64","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.eurpsy.2018.07.008","volume":"54","author":"P Robert","year":"2018","unstructured":"Robert P, Lanctot KL, Aguera-Ortiz L, Aalten P, Bremond F, Defrancesco M, et al. Is it time to revise the diagnostic criteria for apathy in brain disorders? The 2018 international consensus group. Eur Psychiatry. 2018;54:71\u20136.","journal-title":"Eur Psychiatry"},{"issue":"5","key":"424_CR65","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1176\/appi.ajp.2019.19090915","volume":"177","author":"SH Siddiqi","year":"2020","unstructured":"Siddiqi SH, Taylor SF, Cooke D, Pascual-Leone A, George MS, Fox MD. Distinct symptom-specific treatment targets for circuit-based neuromodulation. Am J Psychiatry. 2020;177(5):435\u201346.","journal-title":"Am J Psychiatry"},{"issue":"7","key":"424_CR66","doi-asserted-by":"publisher","first-page":"a006338","DOI":"10.1101\/cshperspect.a006338","volume":"2","author":"L Mucke","year":"2012","unstructured":"Mucke L, Selkoe DJ. Neurotoxicity of amyloid beta-protein: synaptic and network dysfunction. Cold Spring Harb Perspect Med. 2012;2(7):a006338.","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"6","key":"424_CR67","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.jagp.2017.01.017","volume":"25","author":"GH Weissberger","year":"2017","unstructured":"Weissberger GH, Melrose RJ, Narvaez TA, Harwood D, Mandelkern MA, Sultzer DL. (18)F-Fluorodeoxyglucose positron emission tomography cortical metabolic activity associated with distinct agitation behaviors in Alzheimer disease. Am J Geriatr Psychiatry. 2017;25(6):569\u201379.","journal-title":"Am J Geriatr Psychiatry"},{"issue":"7","key":"424_CR68","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1001\/archneur.64.7.1015","volume":"64","author":"GA Marshall","year":"2007","unstructured":"Marshall GA, Monserratt L, Harwood D, Mandelkern M, Cummings JL, Sultzer DL. Positron emission tomography metabolic correlates of apathy in Alzheimer disease. Arch Neurol. 2007;64(7):1015\u201320.","journal-title":"Arch Neurol"},{"issue":"7","key":"424_CR69","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1016\/j.jagp.2012.10.028","volume":"22","author":"J Koppel","year":"2014","unstructured":"Koppel J, Sunday S, Goldberg TE, Davies P, Christen E, Greenwald BS, et al. Psychosis in Alzheimer's disease is associated with frontal metabolic impairment and accelerated decline in working memory: findings from the Alzheimer's disease neuroimaging initiative. Am J Geriatr Psychiatry. 2014;22(7):698\u2013707.","journal-title":"Am J Geriatr Psychiatry"},{"issue":"10","key":"424_CR70","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.2174\/1567205013666160502123607","volume":"13","author":"D Van Dam","year":"2016","unstructured":"Van Dam D, Vermeiren Y, Dekker AD, Naude PJ, Deyn PP. Neuropsychiatric disturbances in Alzheimer's disease: what have we learned from neuropathological studies? Curr Alzheimer Res. 2016;13(10):1145\u201364.","journal-title":"Curr Alzheimer Res"},{"issue":"4","key":"424_CR71","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.jagp.2019.09.009","volume":"28","author":"GT Grossberg","year":"2020","unstructured":"Grossberg GT, Kohegyi E, Mergel V, Josiassen MK, Meulien D, Hobart M, et al. Efficacy and safety of brexpiprazole for the treatment of agitation in Alzheimer's dementia: two 12-week, randomized, double-blind, placebo-controlled trials. Am J Geriatr Psychiatry. 2020;28(4):383\u2013400.","journal-title":"Am J Geriatr Psychiatry"},{"issue":"12","key":"424_CR72","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1001\/jama.2015.10214","volume":"314","author":"JL Cummings","year":"2015","unstructured":"Cummings JL, Lyketsos CG, Peskind ER, Porsteinsson AP, Mintzer JE, Scharre DW, et al. Effect of dextromethorphan-quinidine on agitation in patients with Alzheimer disease dementia: a randomized clinical trial. JAMA. 2015;314(12):1242\u201354.","journal-title":"JAMA."},{"issue":"11","key":"424_CR73","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1016\/j.jagp.2019.05.002","volume":"27","author":"N Herrmann","year":"2019","unstructured":"Herrmann N, Ruthirakuhan M, Gallagher D, Verhoeff N, Kiss A, Black SE, et al. Randomized placebo-controlled trial of nabilone for agitation in Alzheimer's disease. Am J Geriatr Psychiatry. 2019;27(11):1161\u201373.","journal-title":"Am J Geriatr Psychiatry"},{"issue":"9","key":"424_CR74","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1097\/JGP.0b013e3181ab8c61","volume":"17","author":"LY Wang","year":"2009","unstructured":"Wang LY, Shofer JB, Rohde K, Hart KL, Hoff DJ, McFall YH, et al. Prazosin for the treatment of behavioral symptoms in patients with Alzheimer disease with agitation and aggression. Am J Geriatr Psychiatry. 2009;17(9):744\u201351.","journal-title":"Am J Geriatr Psychiatry"},{"issue":"9916","key":"424_CR75","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/S0140-6736(13)62106-6","volume":"383","author":"J Cummings","year":"2014","unstructured":"Cummings J, Isaacson S, Mills R, Williams H, Chi-Burris K, Corbett A, et al. Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet. 2014;383(9916):533\u201340.","journal-title":"Lancet."},{"issue":"3","key":"424_CR76","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/S1474-4422(18)30039-5","volume":"17","author":"C Ballard","year":"2018","unstructured":"Ballard C, Banister C, Khan Z, Cummings J, Demos G, Coate B, et al. Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer's disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study. Lancet Neurol. 2018;17(3):213\u201322.","journal-title":"Lancet Neurol"},{"issue":"4","key":"424_CR77","first-page":"253","volume":"5","author":"J Cummings","year":"2018","unstructured":"Cummings J, Ballard C, Tariot P, Owen R, Foff E, Youakim J, et al. Pimavanserin: potential treatment for dementia-related psychosis. J Prev Alzheimers Dis. 2018;5(4):253\u20138.","journal-title":"J Prev Alzheimers Dis"},{"issue":"12","key":"424_CR78","doi-asserted-by":"publisher","first-page":"2300","DOI":"10.1212\/WNL.44.12.2300","volume":"44","author":"Y Stern","year":"1994","unstructured":"Stern Y, Albert M, Brandt J, Jacobs DM, Tang MX, Marder K, et al. Utility of extrapyramidal signs and psychosis as predictors of cognitive and functional decline, nursing home admission, and death in Alzheimer's disease: prospective analyses from the predictors study. Neurology. 1994;44(12):2300\u20137.","journal-title":"Neurology."},{"issue":"6","key":"424_CR79","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1212\/WNL.48.6.1521","volume":"48","author":"OL Lopez","year":"1997","unstructured":"Lopez OL, Brenner RP, Becker JT, Ulrich RF, Boller F, DeKosky ST. EEG spectral abnormalities and psychosis as predictors of cognitive and functional decline in probable Alzheimer's disease. Neurology. 1997;48(6):1521\u20135.","journal-title":"Neurology."},{"issue":"4","key":"424_CR80","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.jagp.2018.12.013","volume":"27","author":"CW Zhu","year":"2019","unstructured":"Zhu CW, Grossman HT, Sano M. Why do they just sit? Apathy as a core symptom of Alzheimer disease. Am J Geriatr Psychiatry. 2019;27(4):395\u2013405.","journal-title":"Am J Geriatr Psychiatry"},{"issue":"2","key":"424_CR81","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1177\/0891988719882102","volume":"33","author":"J Cummings","year":"2020","unstructured":"Cummings J. The neuropsychiatric inventory: development and applications. J Geriatr Psychiatry Neurol. 2020;33(2):73\u201384.","journal-title":"J Geriatr Psychiatry Neurol"},{"issue":"8","key":"424_CR82","doi-asserted-by":"publisher","first-page":"810","DOI":"10.4088\/JCP.12m08099","volume":"74","author":"PB Rosenberg","year":"2013","unstructured":"Rosenberg PB, Lanctot KL, Drye LT, Herrmann N, Scherer RW, Bachman DL, et al. Safety and efficacy of methylphenidate for apathy in Alzheimer's disease: a randomized, placebo-controlled trial. J Clin Psychiatry. 2013;74(8):810\u20136.","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"424_CR83","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s13063-017-2406-5","volume":"19","author":"RW Scherer","year":"2018","unstructured":"Scherer RW, Drye L, Mintzer J, Lanctot K, Rosenberg P, Herrmann N, et al. The apathy in dementia methylphenidate trial 2 (ADMET 2): study protocol for a randomized controlled trial. Trials. 2018;19(1):46.","journal-title":"Trials."},{"key":"424_CR84","volume":"5","author":"MT Ruthirakuhan","year":"2018","unstructured":"Ruthirakuhan MT, Herrmann N, Abraham EH, Chan S, Lanctot KL. Pharmacological interventions for apathy in Alzheimer's disease. Cochrane Database Syst Rev. 2018;5:CD012197.","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"424_CR85","doi-asserted-by":"publisher","first-page":"633","DOI":"10.3233\/JAD-131385","volume":"39","author":"F Stella","year":"2014","unstructured":"Stella F, Radanovic M, Aprahamian I, Canineu PR, de Andrade LP, Forlenza OV. Neurobiological correlates of apathy in Alzheimer's disease and mild cognitive impairment: a critical review. J Alzheimers Dis. 2014;39(3):633\u201348.","journal-title":"J Alzheimers Dis"},{"issue":"11","key":"424_CR86","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1590\/0004-282x20190149","volume":"77","author":"CR Borges","year":"2019","unstructured":"Borges CR, Poyares D, Piovezan R, Nitrini R, Brucki S. Alzheimer's disease and sleep disturbances: a review. Arq Neuropsiquiatr. 2019;77(11):815\u201324.","journal-title":"Arq Neuropsiquiatr"},{"key":"424_CR87","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.smrv.2014.03.007","volume":"19","author":"L Peter-Derex","year":"2015","unstructured":"Peter-Derex L, Yammine P, Bastuji H, Croisile B. Sleep and Alzheimer's disease. Sleep Med Rev. 2015;19:29\u201338.","journal-title":"Sleep Med Rev"},{"issue":"2","key":"424_CR88","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/nrneurol.2013.269","volume":"10","author":"YE Ju","year":"2014","unstructured":"Ju YE, Lucey BP, Holtzman DM. Sleep and Alzheimer disease pathology--a bidirectional relationship. Nat Rev Neurol. 2014;10(2):115\u20139.","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"424_CR89","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41386-019-0478-5","volume":"45","author":"C Wang","year":"2020","unstructured":"Wang C, Holtzman DM. Bidirectional relationship between sleep and Alzheimer's disease: role of amyloid, tau, and other factors. Neuropsychopharmacology. 2020;45(1):104\u201320.","journal-title":"Neuropsychopharmacology."},{"issue":"3","key":"424_CR90","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1002\/alz.12035","volume":"16","author":"WJ Herring","year":"2020","unstructured":"Herring WJ, Ceesay P, Snyder E, Bliwise D, Budd K, Hutzelmann J, et al. Polysomnographic assessment of suvorexant in patients with probable Alzheimer's disease dementia and insomnia: a randomized trial. Alzheimers Dement. 2020;16(3):541\u201351.","journal-title":"Alzheimers Dement"},{"issue":"4","key":"424_CR91","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s40265-020-01276-1","volume":"80","author":"LJ Scott","year":"2020","unstructured":"Scott LJ. Lemborexant: first approval. Drugs. 2020;80(4):425\u201332.","journal-title":"Drugs."},{"issue":"2","key":"424_CR92","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.jsmc.2009.01.009","volume":"4","author":"PC Zee","year":"2009","unstructured":"Zee PC, Vitiello MV. Circadian rhythm sleep disorder: irregular sleep wake rhythm type. Sleep Med Clin. 2009;4(2):213\u20138.","journal-title":"Sleep Med Clin"},{"issue":"6429","key":"424_CR93","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1126\/science.aav2546","volume":"363","author":"JK Holth","year":"2019","unstructured":"Holth JK, Fritschi SK, Wang C, Pedersen NP, Cirrito JR, Mahan TE, et al. The sleep-wake cycle regulates brain interstitial fluid tau in mice and CSF tau in humans. Science. 2019;363(6429):880\u20134.","journal-title":"Science."},{"issue":"12","key":"424_CR94","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1017\/S1041610215001106","volume":"27","author":"PB Rosenberg","year":"2015","unstructured":"Rosenberg PB, Drye LT, Porsteinsson AP, Pollock BG, Devanand DP, Frangakis C, et al. Change in agitation in Alzheimer's disease in the placebo arm of a nine-week controlled trial. Int Psychogeriatr. 2015;27(12):2059\u201367.","journal-title":"Int Psychogeriatr"},{"key":"424_CR95","doi-asserted-by":"publisher","first-page":"169","DOI":"10.2147\/CLEP.S188752","volume":"11","author":"DRT Laursen","year":"2019","unstructured":"Laursen DRT, Paludan-Muller AS, Hrobjartsson A. Randomized clinical trials with run-in periods: frequency, characteristics and reporting. Clin Epidemiol. 2019;11:169\u201384.","journal-title":"Clin Epidemiol"},{"issue":"2","key":"424_CR96","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1001\/jama.2020.6463","volume":"324","author":"X Huo","year":"2020","unstructured":"Huo X, Armitage J. Use of run-in periods in randomized trials. JAMA. 2020;324(2):188\u20139.","journal-title":"JAMA."},{"issue":"4","key":"424_CR97","doi-asserted-by":"publisher","first-page":"323","DOI":"10.2174\/1567205043332027","volume":"1","author":"JL Cummings","year":"2004","unstructured":"Cummings JL, Tractenberg RE, Gamst A, Teri L, Masterman D, Thal LJ. Regression to the mean: implications for clinical trials of psychotropic agents in dementia. Curr Alzheimer Res. 2004;1(4):323\u20138.","journal-title":"Curr Alzheimer Res"},{"issue":"1572","key":"424_CR98","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1098\/rstb.2010.0384","volume":"366","author":"P Enck","year":"2011","unstructured":"Enck P, Klosterhalfen S, Weimer K, Horing B, Zipfel S. The placebo response in clinical trials: more questions than answers. Philos Trans R Soc Lond Ser B Biol Sci. 2011;366(1572):1889\u201395.","journal-title":"Philos Trans R Soc Lond Ser B Biol Sci"},{"issue":"1","key":"424_CR99","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1055\/s-0037-1621702","volume":"9","author":"L Houston","year":"2018","unstructured":"Houston L, Probst Y, Yu P, Martin A. Exploring data quality management within clinical trials. Appl Clin Inform. 2018;9(1):72\u201381.","journal-title":"Appl Clin Inform"},{"issue":"5","key":"424_CR100","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1177\/1740774512456454","volume":"9","author":"R Boessen","year":"2012","unstructured":"Boessen R, Knol MJ, Groenwold RH, Grobbee DE, Roes KC. Increasing trial efficiency by early reallocation of placebo nonresponders in sequential parallel comparison designs: application to antidepressant trials. Clin Trials. 2012;9(5):578\u201387.","journal-title":"Clin Trials"},{"issue":"9","key":"424_CR101","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1002\/gps.2630","volume":"26","author":"DP Devanand","year":"2011","unstructured":"Devanand DP, Pelton GH, Cunqueiro K, Sackeim HA, Marder K. A 6-month, randomized, double-blind, placebo-controlled pilot discontinuation trial following response to haloperidol treatment of psychosis and agitation in Alzheimer's disease. Int J Geriatr Psychiatry. 2011;26(9):937\u201343.","journal-title":"Int J Geriatr Psychiatry"},{"issue":"16","key":"424_CR102","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1056\/NEJMoa1114058","volume":"367","author":"DP Devanand","year":"2012","unstructured":"Devanand DP, Mintzer J, Schultz SK, Andrews HF, Sultzer DL, de la Pena D, et al. Relapse risk after discontinuation of risperidone in Alzheimer's disease. N Engl J Med. 2012;367(16):1497\u2013507.","journal-title":"N Engl J Med"},{"issue":"16","key":"424_CR103","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1056\/NEJMoa1911772","volume":"382","author":"KS Koblan","year":"2020","unstructured":"Koblan KS, Kent J, Hopkins SC, Krystal JH, Cheng H, Goldman R, et al. A non-D2-receptor-binding drug for the treatment of schizophrenia. N Engl J Med. 2020;382(16):1497\u2013506.","journal-title":"N Engl J Med"},{"key":"424_CR104","doi-asserted-by":"publisher","unstructured":"Yang AC, Tsai SJ. New Targets for Schizophrenia Treatment beyond the Dopamine Hypothesis. Int J Mol Sci. 2017;18(8):1689. https:\/\/doi.org\/10.3390\/ijms18081689. PMID: 28771182.","DOI":"10.3390\/ijms18081689"},{"key":"424_CR105","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.jad.2015.09.069","volume":"190","author":"QF Zhao","year":"2016","unstructured":"Zhao QF, Tan L, Wang HF, Jiang T, Tan MS, Tan L, et al. The prevalence of neuropsychiatric symptoms in Alzheimer's disease: systematic review and meta-analysis. J Affect Disord. 2016;190:264\u201371.","journal-title":"J Affect Disord"},{"issue":"3","key":"424_CR106","doi-asserted-by":"publisher","first-page":"725","DOI":"10.3233\/JAD-161247","volume":"58","author":"V Orgeta","year":"2017","unstructured":"Orgeta V, Tabet N, Nilforooshan R, Howard R. Efficacy of antidepressants for depression in Alzheimer's disease: systematic review and meta-analysis. J Alzheimers Dis. 2017;58(3):725\u201333.","journal-title":"J Alzheimers Dis"},{"key":"424_CR107","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.pharmthera.2019.04.009","volume":"201","author":"CA Browne","year":"2019","unstructured":"Browne CA, Lucki I. Targeting opioid dysregulation in depression for the development of novel therapeutics. Pharmacol Ther. 2019;201:51\u201376.","journal-title":"Pharmacol Ther"},{"key":"424_CR108","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.neubiorev.2018.04.002","volume":"90","author":"JB Price","year":"2018","unstructured":"Price JB, Bronars C, Erhardt S, Cullen KR, Schwieler L, Berk M, et al. Bioenergetics and synaptic plasticity as potential targets for individualizing treatment for depression. Neurosci Biobehav Rev. 2018;90:212\u201320.","journal-title":"Neurosci Biobehav Rev"},{"issue":"5","key":"424_CR109","doi-asserted-by":"publisher","first-page":"636","DOI":"10.2174\/1570159X13666150630175044","volume":"13","author":"JD Rosenblat","year":"2015","unstructured":"Rosenblat JD, McIntyre RS, Alves GS, Fountoulakis KN, Carvalho AF. Beyond monoamines-novel targets for treatment-resistant depression: a comprehensive review. Curr Neuropharmacol. 2015;13(5):636\u201355.","journal-title":"Curr Neuropharmacol"},{"key":"424_CR110","doi-asserted-by":"publisher","first-page":"172757","DOI":"10.1016\/j.pbb.2019.172757","volume":"185","author":"M Takakuwa","year":"2019","unstructured":"Takakuwa M, Watanabe Y, Tanaka K, Ishii T, Kagaya K, Taniguchi H, et al. Antipsychotic-like effects of a novel phosphodiesterase 10A inhibitor T-251 in rodents. Pharmacol Biochem Behav. 2019;185:172757.","journal-title":"Pharmacol Biochem Behav"},{"issue":"4","key":"424_CR111","doi-asserted-by":"publisher","first-page":"381","DOI":"10.2174\/1381612825666190312102444","volume":"25","author":"C Tomasetti","year":"2019","unstructured":"Tomasetti C, Montemitro C, Fiengo ALC, Santone C, Orsolini L, Valchera A, et al. Novel pathways in the treatment of major depression: focus on the glutamatergic system. Curr Pharm Des. 2019;25(4):381\u20137.","journal-title":"Curr Pharm Des"},{"issue":"1","key":"424_CR112","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/WAD.0000000000000144","volume":"30","author":"J Sevigny","year":"2016","unstructured":"Sevigny J, Suhy J, Chiao P, Chen T, Klein G, Purcell D, et al. Amyloid PET screening for enrichment of early-stage Alzheimer disease clinical trials: experience in a phase 1b clinical trial. Alzheimer Dis Assoc Disord. 2016;30(1):1\u20137.","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"7691","key":"424_CR113","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/nature25456","volume":"554","author":"A Nakamura","year":"2018","unstructured":"Nakamura A, Kaneko N, Villemagne VL, Kato T, Doecke J, Dore V, et al. High performance plasma amyloid-beta biomarkers for Alzheimer's disease. Nature. 2018;554(7691):249\u201354.","journal-title":"Nature."},{"issue":"17","key":"424_CR114","doi-asserted-by":"publisher","first-page":"e1647","DOI":"10.1212\/WNL.0000000000008081","volume":"93","author":"SE Schindler","year":"2019","unstructured":"Schindler SE, Bollinger JG, Ovod V, Mawuenyega KG, Li Y, Gordon BA, et al. High-precision plasma beta-amyloid 42\/40 predicts current and future brain amyloidosis. Neurology. 2019;93(17):e1647\u2013e59.","journal-title":"Neurology."},{"issue":"3","key":"424_CR115","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/s41591-020-0755-1","volume":"26","author":"S Janelidze","year":"2020","unstructured":"Janelidze S, Mattsson N, Palmqvist S, Smith R, Beach TG, Serrano GE, et al. Plasma P-tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer's dementia. Nat Med. 2020;26(3):379\u201386.","journal-title":"Nat Med"},{"issue":"1","key":"424_CR116","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s13195-019-0529-5","volume":"11","author":"J Cummings","year":"2019","unstructured":"Cummings J, Feldman HH, Scheltens P. The \"rights\" of precision drug development for Alzheimer's disease. Alzheimers Res Ther. 2019;11(1):76.","journal-title":"Alzheimers Res Ther"},{"key":"424_CR117","doi-asserted-by":"publisher","first-page":"104471","DOI":"10.1016\/j.neuint.2019.104471","volume":"129","author":"J Chen","year":"2019","unstructured":"Chen J, Zook D, Crickard L, Tabatabaei A. Effect of phosphodiesterase (1B, 2A, 9A and 10A) inhibitors on central nervous system cyclic nucleotide levels in rats and mice. Neurochem Int. 2019;129:104471.","journal-title":"Neurochem Int"},{"issue":"3","key":"424_CR118","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1017\/S1461145701002528","volume":"4","author":"SG Potkin","year":"2001","unstructured":"Potkin SG, Anand R, Fleming K, Alva G, Keator D, Carreon D, et al. Brain metabolic and clinical effects of rivastigmine in Alzheimer's disease. Int J Neuropsychopharmacol. 2001;4(3):223\u201330.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"Suppl 4","key":"424_CR119","first-page":"S53","volume":"155","author":"A Nordberg","year":"1999","unstructured":"Nordberg A. PET studies and cholinergic therapy in Alzheimer's disease. Rev Neurol (Paris). 1999;155(Suppl 4):S53\u201363.","journal-title":"Rev Neurol (Paris)"},{"issue":"3","key":"424_CR120","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1097\/01.yco.0000218602.25346.c6","volume":"19","author":"BC Dickerson","year":"2006","unstructured":"Dickerson BC. Functional magnetic resonance imaging of cholinergic modulation in mild cognitive impairment. Curr Opin Psychiatry. 2006;19(3):299\u2013306.","journal-title":"Curr Opin Psychiatry"},{"issue":"9","key":"424_CR121","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1001\/archneur.64.9.1323","volume":"64","author":"J Harrison","year":"2007","unstructured":"Harrison J, Minassian SL, Jenkins L, Black RS, Koller M, Grundman M. A neuropsychological test battery for use in Alzheimer disease clinical trials. Arch Neurol. 2007;64(9):1323\u20139.","journal-title":"Arch Neurol"},{"issue":"1","key":"424_CR122","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1177\/1533317514522852","volume":"30","author":"S Zygouris","year":"2015","unstructured":"Zygouris S, Tsolaki M. Computerized cognitive testing for older adults: a review. Am J Alzheimers Dis Other Dement. 2015;30(1):13\u201328.","journal-title":"Am J Alzheimers Dis Other Dement"},{"key":"424_CR123","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.dadm.2017.03.002","volume":"8","author":"RJ Jutten","year":"2017","unstructured":"Jutten RJ, Peeters CFW, Leijdesdorff SMJ, Visser PJ, Maier AB, Terwee CB, et al. Detecting functional decline from normal aging to dementia: development and validation of a short version of the Amsterdam IADL questionnaire. Alzheimers Dement (Amst). 2017;8:26\u201335.","journal-title":"Alzheimers Dement (Amst)"},{"issue":"1","key":"424_CR124","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.trci.2017.01.004","volume":"3","author":"RJ Jutten","year":"2017","unstructured":"Jutten RJ, Harrison J, de Jong FJ, Aleman A, Ritchie CW, Scheltens P, et al. A composite measure of cognitive and functional progression in Alzheimer's disease: Design of the Capturing Changes in cognition study. Alzheimers Dement (N Y). 2017;3(1):130\u20138.","journal-title":"Alzheimers Dement (N Y)."},{"issue":"9","key":"424_CR125","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1136\/jnnp-2015-312383","volume":"87","author":"J Wang","year":"2016","unstructured":"Wang J, Logovinsky V, Hendrix SB, Stanworth SH, Perdomo C, Xu L, et al. ADCOMS: a composite clinical outcome for prodromal Alzheimer's disease trials. J Neurol Neurosurg Psychiatry. 2016;87(9):993\u20139.","journal-title":"J Neurol Neurosurg Psychiatry"}],"updated-by":[{"DOI":"10.1186\/s13024-021-00446-3","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000}}],"container-title":["Molecular Neurodegeneration"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13024-021-00424-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13024-021-00424-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13024-021-00424-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,28]],"date-time":"2023-01-28T03:20:18Z","timestamp":1674876018000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecularneurodegeneration.biomedcentral.com\/articles\/10.1186\/s13024-021-00424-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,13]]},"references-count":125,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["424"],"URL":"https:\/\/doi.org\/10.1186\/s13024-021-00424-9","relation":{"correction":[{"id-type":"doi","id":"10.1186\/s13024-021-00446-3","asserted-by":"object"}]},"ISSN":["1750-1326"],"issn-type":[{"value":"1750-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,13]]},"assertion":[{"value":"26 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2021","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s13024-021-00446-3","URL":"https:\/\/doi.org\/10.1186\/s13024-021-00446-3","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"JC has provided consultation to Acadia, Actinogen, AgeneBio, Alkahest, Alzheon, Annovis, Avanir, Axsome, Biogen, Cassava, Cerecin, Cerevel, Cortexyme, Cytox, EIP Pharma, Eisai, Foresight, GemVax, Genentech, Green Valley, Grifols, Karuna, Merck, Novo Nordisk, Otsuka, Resverlogix, Roche, Samumed, Samus, Signant Health, Suven, and United Neuroscience pharmaceutical and assessment companies. Dr. Cummings has stock options in ADAMAS, AnnovisBio, MedAvante, BiOasis. Dr. Cummings owns the copyright of the Neuropsychiatric Inventory.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2"}}